In this episode, we look at a life sciences instrumentation company in the genome analysis space called Bionano Genomics (BNGO.Q). The company develops and markets the Saphyr system, a platform used for ultra-sensitive and ultra-specific structural variation detection. This Optical Genome Mapping (OGM) platform can detect these large Structural Variations responsible for genetic diseases and can reveal them at sensitivities as high as 99%, with false-positive rates below 2%. But how well has the Saphyr worked BNGO so far? We look at their tech, financial statements and stock price. Tune in!
To Invest or Not: Bionano Genomics (BNGO.Q)
Latest Articles
- Brera Holdings (BREA.Q) pioneering pubco sports investment model, but is it a win?
- “The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
- Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
- Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
- Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading uranium wealth wealth creation weed
by
Leave a Reply